|
Clinical features present at T1
|
Model 1: remissiona at T2 (N = 48)
|
Model 2: extended remissiona (N = 31)
|
Model 3: durable remissiona (N = 13)
|
|---|
|
OR
|
95% CI
|
P value
|
OR
|
95% CI
|
P value
|
OR
|
95% CI
|
P value
|
|---|
|
Increased CKb
|
-
|
-
|
-
|
3.18
|
1.17–8.67
|
.024*
|
-
|
-
|
-
|
|
Facial erythemab
|
-
|
-
|
-
|
-
|
-
|
-
|
0.11
|
0.01–0.81
|
.030*
|
|
Digital ulcersb
|
-
|
-
|
-
|
0.25
|
0.08–0.77
|
.015*
|
-
|
-
|
-
|
|
Trombocytopheniab,
c
|
0.05
|
0.01–-0.44
|
.006**
|
-
|
-
|
-
|
-
|
-
|
-
|
|
FVC % pred (pr 10%)
|
1.37
|
1.04–1.79
|
.026*
|
1.56
|
1.13–2.16
|
.007**
|
1.71
|
1.04–2.80
|
.033*
|
|
NSAID medication
|
-
|
-
|
-
|
-
|
-
|
-
|
0.05
|
0.00–0.73
|
.028*
|
|
Negative anti-RNP
|
-
|
-
|
-
|
-
|
-
|
-
|
15.0
|
1.97–113.59
|
.009**
|
- Area under receiver operating curve (ROC) was 73% for Model 1, 76% for Model 2 and 83% for Model 3
-
T1 time point 1, T2 time point 2, CK creatine kinase, FVC % pred percentage of predicted forced vital capacity, NSAIDs nonsteroidal anti-inflammatory drugs, anti-RNP anti-ribonucleoprotein, ROC receiver operating characteristic
- * P <.05; ** P <.01
-
aIncludes patients in remission both on and off therapy; medications allowed were hydroxychloroquine, NSAIDs, corticosteroids at ≤ 5 mg daily, calcium channel blockers, methotrexate, mycophenolate and azathioprine
-
bEver present at T1
-
cThrombocytes <100 × 109 platelets/L
